↓ Skip to main content

Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence

Overview of attention for article published in Breast Cancer Research, August 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

blogs
1 blog
twitter
3 tweeters

Citations

dimensions_citation
41 Dimensions

Readers on

mendeley
85 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence
Published in
Breast Cancer Research, August 2015
DOI 10.1186/s13058-015-0611-2
Pubmed ID
Authors

Heleen K Bronsveld, Bas ter Braak, Øystein Karlstad, Peter Vestergaard, Jakob Starup-Linde, Marloes T Bazelier, Marie L De Bruin, Anthonius de Boer, Christine L E Siezen, Bob van de Water, Jan Willem van der Laan, Marjanka K Schmidt

Abstract

Several studies have suggested that anti-diabetic insulin analogue treatment might increase cancer risk. The aim of this study was to review the postulated association between insulin and insulin analogue treatment and breast cancer development, and plausible mechanisms. A systematic literature search was performed on breast cell-line, animal and human studies using the key words 'insulin analogue' and 'breast neoplasia' in MEDLINE at PubMed, EMBASE, and ISI Web of Science databases. A quantitative and qualitative review was performed on the epidemiological data; due to a limited number of reported estimates, a meta-analysis was performed for glargine only. A comprehensive overview was composed for in vitro and animal studies. Protein and gene expression was analysed for the cell lines most frequently used in the included in vitro studies. In total 16 in vitro, 5 animal, 2 in vivo human and 29 epidemiological papers were included. Insulin AspB10 showed mitogenic properties in vitro and in animal studies. Glargine was the only clinically available insulin analogue for which an increased proliferative potential was found in breast cancer cell lines. However, the pooled analysis of 13 epidemiological studies did not show evidence for an association between insulin glargine treatment and an increased breast cancer risk (HR 1.04; 95 % CI 0.91-1.17; p=0.49) versus no glargine in patients with diabetes mellitus. It has to be taken into account that the number of animal studies was limited, and epidemiological studies were underpowered and suffered from methodological limitations. There is no compelling evidence that any clinically available insulin analogue (Aspart, Determir, Glargine, Glulisine or Lispro), nor human insulin increases breast cancer risk. Overall, the data suggests that insulin treatment is not involved in breast tumour initiation, but might induce breast tumour progression by up regulating mitogenic signalling pathways.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Unknown 84 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 20%
Researcher 11 13%
Other 8 9%
Student > Ph. D. Student 7 8%
Student > Master 7 8%
Other 23 27%
Unknown 12 14%
Readers by discipline Count As %
Medicine and Dentistry 31 36%
Agricultural and Biological Sciences 7 8%
Biochemistry, Genetics and Molecular Biology 7 8%
Pharmacology, Toxicology and Pharmaceutical Science 7 8%
Nursing and Health Professions 6 7%
Other 11 13%
Unknown 16 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2016.
All research outputs
#1,405,850
of 15,049,257 outputs
Outputs from Breast Cancer Research
#178
of 1,608 outputs
Outputs of similar age
#27,272
of 235,881 outputs
Outputs of similar age from Breast Cancer Research
#3
of 18 outputs
Altmetric has tracked 15,049,257 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,608 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,881 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.